Agree Realty Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joel N. Agree
- Full Time Employees
- 75
- Sector
- Real Estate
- Industry
- REIT - Retail
- Address
- 70 East Long Lake Road Royal Oak MI United States of America 48304
- IPO Date
- Apr 15, 1994
- CIK
- 0000917251
- Website
- agreerealty.com
- Similar Companies
- Business
- Agree Realty Corporation (NYSE: ADC), a fully integrated, self-administered and self-managed real estate investment trust founded in 1971 and headquartered in Royal Oak, Michigan, acquires, develops, owns and manages single-tenant retail properties net leased on a long-term basis primarily to investment-grade national and regional omni-channel retailers including Walmart, Advance Auto Parts, Dollar General, AutoZone, Gerber Collision, CVS, Burlington, Dollar Tree, Best Buy, Academy Sports, and Academy Sports; as of September 30, 2025, the portfolio comprises 2,603 properties containing approximately 54 million square feet of gross leasable area located across all 50 U.S. states, with 67% of annualized base rents derived from investment-grade tenants and 10.9% from ground leases. The company operates through acquisition, ground-up development, and its Developer Funding Platform, targeting properties in 28 retail sectors with a focus on stable, fee-simple ownership and weighted-average lease terms exceeding 10 years. In 2024, Agree Realty executed $951 million in total real estate investments including $867 million in 242 acquisitions at a 7.5% weighted-average cap rate (73.3% investment-grade in Q4), raised approximately $1.1 billion in forward equity through public offerings and its at-the-market program, closed a $350 million 5.5-year delayed draw term loan in November 2025, and strengthened liquidity to over $2.0 billion with no material debt maturities until 2028; for 2025, it projects $1.1 billion to $1.3 billion in investment volume representing a 26% increase at the midpoint.
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Agree Realty Is Becoming More And More Attractive, But I'm Not Buying Yet
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
U.S. REIT At-The-Market Activity Dips In Q1 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
Agree Realty Declares Monthly Common and Preferred Dividends
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
Agree Realty: Bigger Investments, Stronger Growth Amid Uncertainty Puts Them In A Different League
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026